CN · Field Sheet
FIELD SHEET — SAW PALMETTO MFI-SAWPAL-20261019-FS
Survey index / SAW PALMETTO

Saw Palmetto.

Serenoa repens
Palm-fruit extract; urinary-symptom and BPH literature.
SEALED MFI-SAWPAL-20261019-FS · RELEASED 2026-10-19
SHEET FINGERPRINTMFI-SAWPAL-20261019-FS
211INCLUDED
1,506EXCLUDED
25DUPLICATE
16NON-TRANSFERABLE
2OUT OF CUTOFF
Survey totalsScroll ↓
1,760records surveyed
211studies
23claims graded
131observations
5,933graph nodes

Claim records

2 shown · bounded preview
RECORD PREVIEW · FIELD RECORD ×2BOUNDED — REAL RELEASED DATA
CLAIM · CLM-9d6d97f9c4e025c8GRADE VERY_LOW
saw palmetto constituents — inflammation
direction BENEFIT · dose 320 mg · duration 12 weeks; 28 days; 4 weeks
Grade basis — weakest-link ceilings
MODERATEdesign
LOWdirectness
MODERATEextraction
LOWconfidence
LOWmethodology
MODERATEconsistency
MODERATEnumeric
7bound studies
Bound studies (4 shown of 7)
STU-18078bc979f73fa4
ANIMAL · ANIMAL · 2020 · RoB INSUFFICIENT_INFORMATION
6 endpoints
STU-3deea6088a9c2cf6
ANIMAL · ANIMAL · 2019 · 28 days · RoB INSUFFICIENT_INFORMATION
2 endpoints
STU-5cec11a081010aa7
TRIAL · HUMAN · 2023 · RoB HIGH_RISK
2 endpoints
STU-8f815f432373e084
IN_VITRO · IN_VITRO · 2025 · RoB INSUFFICIENT_INFORMATION
1 endpoints
Quantitative observations
observation 30 · validated
observation p < 0.001 · failed extraction
observation 4 weeks · failed extraction
Opposition screen
SCREEN · 9 candidates considered · 1 bound as opposing
SYNTHESIS SYN-57db9c30049269 — outcome QUALITATIVE_ONLY · BENEFIT ×7 · not_assessed_quantitatively · 7 members
PROVENANCE → epmc:32885876, epmc:31623582, epmc:37276165 · PKG 021a0b91a6d5112c…
CLAIM · CLM-d31e41e7465f4211GRADE LOW
saw palmetto constituents — mood
direction BENEFIT · dose UNSPECIFIED · duration 12 weeks; 16 weeks; 8 weeks
Grade basis — weakest-link ceilings
MODERATEdesign
LOWdirectness
MODERATEextraction
LOWconfidence
LOWmethodology
MODERATEconsistency
MODERATEnumeric
4bound studies
Bound studies (4 shown of 4)
STU-105d887786b47eb9
UNSPECIFIED · HUMAN · 2018 · 8 weeks · RoB NOT_ASSESSABLE
1 endpoints
STU-5cec11a081010aa7
TRIAL · HUMAN · 2023 · RoB HIGH_RISK
2 endpoints
STU-611bffe12c3b6244
RCT · HUMAN · 2025 · 12 weeks · RoB SOME_CONCERNS
1 endpoints
STU-730cd1eba77165ca
RCT · HUMAN · 2023 · 16 weeks · RoB SOME_CONCERNS
1 endpoints
Quantitative observations
observation 8 weeks · failed extraction
observation 150 · validated
observation increased by 5.17% · failed extraction
Opposition screen
SCREEN · 4 candidates considered · 0 bound as opposing
SYNTHESIS SYN-6d5e5405c5c964 — outcome QUALITATIVE_ONLY · BENEFIT ×4 · not_assessed_quantitatively · 4 members
PROVENANCE → epmc:30173449, epmc:37276165, epmc:39042923 · PKG 021a0b91a6d5112c…
Bounded preview — representative records only. The full release ships 23 claims and 131 observations.